Inmune Bio, Inc. (NASDAQ: INMB), a biotechnology company, awarded director Clark Ronnie Duane 100,000 derivative securities on September 15, 2026. Clark’s post-transaction holding was 100,000 derivative securities in Inmune Bio. The award itself accounted for 100.0% of that resulting total. Clark reported a new …
Inmune Bio, Inc. (NASDAQ: INMB) is a biotechnology company. The record also identifies him as a director of Inmune Bio.
Ionis Pharmaceuticals and Roche reported positive interim Phase 3 results for sefaxersen, which met its primary endpoint by improving proteinuria versus placebo. IgA nephropathy can lead to end-stage kidney disease in up to 50% of patients, and the study will continue measuring kidney function.Key …
Armata Pharmaceuticals received an additional $3.7 million in non-dilutive Department of War funding for AP-SA02’s Phase 3 development. The money matters to investors because it is the program’s first Phase 3-specific support and lifts cumulative non-dilutive funding under the award to approximately $32.4 million.Key …
BioCardia, Inc. (NASDAQ: BCDA) is a biotechnology company advancing regulatory milestones for its cardiovascular therapies and delivery technology. The company is targeting a CardiAMP HF submission in Japan during 2026 and plans to move its Helix program into another FDA review step during the …
Pearson PLC (NYSE: PSO), a publishing company focused on books and magazines, is appointing three directors to its board. Michael Barkin and Vivek Sharma will join as independent Non-Executive Directors, while Alex Svensson will become a Non-Executive Director. All three appointments take effect on …
Its board composition changed on September 17 and September 22, 2026, with three directors departing or moving into a different role and three new independent directors appointed.
Terra Innovatum Global N.V. (NASDAQ: NKLR) is an electrical products company. Three independent directors joined its board on September 22, following the resignations of two directors and Peter Hastings’ move into a consulting role on September 17.
All primary endpoints were met, and the treatment was generally safe and well tolerated. The data also showed a 100% response rate after three immunizations, supporting the program’s move toward its next development stage. The trial is randomized, double-blind and placebo-controlled.
Its supply and quality arrangement with Harvey Industries Group Pty Ltd now has a further term that can run through December 31, 2026, subject to an earlier replacement agreement.